(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person *

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Gryaznov Sergei			2. Issuer Name and Ticker or Trading Symbol MAIA Biotechnology, Inc. [MAIA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X_ Officer (give title below) Other (specify below) Chief Scientific Officer						
444 WEST LAKE STREET,, SUITE 1700				3. Date of Earliest Transaction (Month/Day/Year) 08/01/2022											
(Street) CHICAGO, IL 60606				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City	<i>(</i>)	(State)	(Zip)	Table I - Non-Derivative Securities Acqui						iired, Dis	red, Disposed of, or Beneficially Owned				
1. Title of Security (Instr. 3)		I	ate Ionth/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Year	(Instr. 8)			4. Securities Acquired (A) or Disposed of (I) (Instr. 3, 4 and 5)		of (D)			Following n(s)	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
					C	Code	V	Amount	(A) or (D)	Price				or Indirect (Ir (I) (Instr. 4)	(Instr. 4)
Common	Stock	(08/01/2022		I	o (1)		3,000	A	\$ 5	24,511			D	
				Derivative Secur		cquir	conta the fo	ined in orm disp sposed o	this for plays a f, or Ber	m are curre reficia	not required noting valid	uired to re d OMB co	nformation espond unles ntrol number	s	474 (9-02
1. Title of	2.	3. Transaction	3A. Deemed	(8/1 /	5.			e Exercis			le and	8. Price of	9. Number of	10.	11. Natu
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Yea		ear) (Instr. 8)			and Expiration Date (Month/Day/Year)			Amount of Underlying Securities (Instr. 3 and 4)	erlying rities	Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Derivative Security: Direct (D) or Indirect	Beneficia
					-, ш	3)					I				

Code V (A) (D)

Shares

Reporting Owners

D	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Gryaznov Sergei 444 WEST LAKE STREET, SUITE 1700 CHICAGO, IL 60606			Chief Scientific Officer				

Signatures

/s/ Sergei M. Gryaznov	08/02/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.